Marcela Cristina Corrêa de Freitas

CV Lattes Google Scholar Citations

Secretaria da Saúde (São Paulo - Estado). Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP (HCMRP). Hemocentro de Ribeirão Preto (Institutional affiliation from the last research proposal)
Birthplace: Brazil

Graduated Degree in Biological Sciences from the Universidade Estadual Paulista Julio de Mesquita Filho (2005) and a degree as Bachelor of Biological Sciences at the Universidade Estadual Paulista Julio de Mesquita Filho (2007). Master of Science from the Faculdade de Medicida de Ribeirão Preto FMRP - USP (2011). Doctor in Sciences, Faculdade de Medicina de Ribeirão Preto FMRP - USP (2015). Develops research projects in the Blood Center of Ribeirão Preto Foundation. She has experience in Morphology, Cell Biology and Molecular Biology, Biotechnology, expression of recombinant proteins in mammalian cell lines. (Source: Lattes Curriculum)

News published in Agência FAPESP Newsletter about the researcher

More items Less items

TITULO

Articles published in other media outlets ( ):

More items Less items

VEICULO: TITULO (DATA)

Scholarships in Brazil

Completed (most recent)

Abstract
The recombinant Factor VII (rFVII) has been the main choice of therapy for hemophiliac patients who develop inhibitors against factor VIII and IX used as treatment. Currently, the product used is produced in hamster cells (BHK-21) which has disadvantages considering the complexity of post-translational modification of this protein and the insertion of glycosylations from murine origin hi…
Plataform for recombinant factor VII production in human cells: development of a high eficient and stable national biopharmaceutical., BP.PD
Cloning and expression of blood coagulation factor VII in human cell lines, BP.DR

Scholarships abroad

Completed (most recent)

Abstract
Inhibitory antibodies development is currently the most significant treatment complication seen in patients with hemophilia and is associated with considerable morbidity and decreased life quality. Approximately 5% of patients with hemophilia B and 20 to 30% of patients with severe hemophilia A, who use factor IX (FIX) and factor VIII (FVIII) replacement therapy, respectively, develop ant…
Post-translational modification profile of recombinant factor VII produced in human cell lines, BE.EP.PD

Virtual Library in numbers * Updated data on August 16, 2025

Total / Available in English

4 / 2	Completed scholarships in Brazil
1 / 1	Completed scholarships abroad
5 / 3	All Scholarships

Associated processes

Most frequent collaborators in research granted by FAPESP

Keywords used by the researcher

Biochemistry Biological Sciences Health Sciences Medicine

Please report errors on the page using this form.

Short URL

Abstract

Abstract